Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 107, Issue 2, Pages 167-173Publisher
ELSEVIER
DOI: 10.1016/S0165-5728(00)00232-0
Keywords
multiple sclerosis; interferon-beta 1a; Avonex (TM); relapsing multiple sclerosis
Categories
Funding
- NINDS NIH HHS [NS 26321] Funding Source: Medline
Ask authors/readers for more resources
Extended observations of the pivotal phase III clinical trial of interferon-beta 1a (IFN beta 1a; Avonex(TM), Biogen) in relapsing MS patients revealed that: (1) active treatment significantly slowed the accumulation of physical disability over time, reduced clinical exacerbations and MRI brain lesions; (2) clinical efficacy did not depend on disability endpoints; (3) active treatment benefited multiple MRI measures of brain lesions: (4) cerebral atrophy occurred over 2 years in relatively mildly disabled patients; and (5) Avonex(TM) could slow the development of atrophy after the first year of treatment. Data from this study were recently used to design a new outcome measure for MS clinical trials (the Multiple Sclerosis Functional Composite), and was also the basis for two ongoing studies of IFN beta 1a: one in patients with monosymptomatic onset of MS and the other in secondary progressive MS. (C) 2000 Elsevier Science B.V: All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available